VANCOUVER, BC / ACCESS Newswire / January 29, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790, WKN:A41QA9) ("LIR" or the "Company")is pleased to announce positive interim results from its ongoing comparative mouse study evaluating cell penetrating peptide (CPP) enabled, needle-free delivery of GLP/GIP-based therapies. In this interim analysis, animals treated with a novel semaglutide/CPP topical formulation demonstrated reduced blood glucose following an oral glucose challenge compa ...